Date: May 16, 2022

Dear Healthcare Professional,

This email is sent to inform you of the important measures, with respect to **TERIFLUNOMIDE,** in the form of available **Educational Materials** and an **Enhanced Pharmacovigilance Pregnancy Active Surveillance Program**. This program, developed with Health Canada, is consistent between participating generic TERIFLUNOMIDE products, marketed by the signatories to this letter, and is included in their respective Product Monographs.

Please note that not all teriflunomide products licensed by participating companies may be available on the market at the time of the issuance of this letter.

Summary

- TERIFLUNOMIDE is **contraindicated** in patients who are pregnant or women of childbearing potential not using reliable contraception.
- TERIFLUNOMIDE may cause fetal harm when administered to a pregnant woman. Pregnancy must be excluded before start of treatment with TERIFLUNOMIDE. Pregnancy must be avoided during TERIFLUNOMIDE treatment or prior to the completion of an accelerated elimination procedure after TERIFLUNOMIDE treatment.
- A TERIFLUNOMIDE **Enhanced Pharmacovigilance Pregnancy Active Surveillance Program** has been established to collect information about the effect of generic teriflunomide exposure during pregnancy. Physicians are encouraged to enroll pregnant women in the **Enhanced Pharmacovigilance Pregnancy Active Surveillance Program**, or pregnant women may enroll themselves, by calling the respective company whose product they were taking (see table below for contact details). The program aims to capture the enrollment of pregnant women who have confirmed or suspected exposure to teriflunomide at any dose, for any number of days, and at any time during pregnancy, including pregnancy within 2 years of teriflunomide discontinuation if accelerated elimination was not used, or within 11 days of teriflunomide discontinuation if accelerated elimination was used. This would include pregnant individuals who are or were taking teriflunomide or who were suspected to have teriflunomide exposure via the semen of a male partner taking teriflunomide.

Educational Materials & Targeted Questionnaires

To assist healthcare professionals and patients minimize risks related to TERIFLUNOMIDE, educational materials and targeted questionnaires have been developed and include:

- Targeted Adverse Event Questionnaires (Hepatic Effects; Interstitial Lung Disease; Pancreatic Disorders; Peripheral Neuropathy; Progressive Multifocal Leukoencephalopathy; Teriflunomide Drug Exposure in Pregnancy Form; Infant Follow-up Form)
- HCP Educational Discussion Guide/ Prescriber Checklist- this educational material was designed to assist prescribers in facilitating discussion and ensuring all appropriate tests are completed prior to initiating treatment. It includes mention of the Teriflunomide Enhanced Pharmacovigilance Pregnancy Active Surveillance Program and encourages healthcare professionals to ensure patients are aware of this program as well as the patient educational materials.
- Educational Patient Card
- Educational Patient Brochure

These educational materials are available for download from the corporate website of each of the participating companies (see table below for contact details).

Background

- TERIFLUNOMIDE is a prescription product indicated as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
- TERIFLUNOMIDE should only be prescribed by clinicians who are experienced in the diagnosis and management of multiple sclerosis.

- TERIFLUNOMIDE may increase the risk of fetal death or teratogenic effects when administered to pregnant women. In animal studies, teriflunomide has been shown to be selectively teratogenic and embryo lethal in multiple species when administered during pregnancy at doses less than those used clinically.

Reporting Adverse Events:

Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Adverse events occurring in patients receiving TERIFLUNOMIDE should be reported to Health Canada and/or the respective company (see table below).

Health Canada

- Call toll-free at 1-866-234-2345; or
- Visit Health Canada's Web page on Adverse Reaction Reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html).

Table: Participating Companies' contact details for reporting adverse events & obtaining Educational Materials:

Auro-Teriflunomide Auro Pharma Inc. 1-855-648-6681 pvteam@auropharma.ca www.auropharma.ca	**Mar-Teriflunomide** Marcan Pharmaceuticals Inc 1-855-627-2261 Fax: 1-613-224-0444 safety.canada@marcanpharma.com www.marcanpharma.com	**Nat-Teriflunomide** Natco Pharma (Canada) Inc. 1-800-296-9329 NatcoCanadaQA@natcopharma.ca www.natcopharma.ca
pms-Teriflunomide Pharmascience Inc. 1-888-550-6060 adr@pharmascience.com www.pharmascience.com	**Sandoz Teriflunomide** Sandoz Canada Inc. 1-800-343-8839 Fax: 1-514-636-3175 medinfo@sandoz.com www.sandoz.ca	**Apo-Teriflunomide** Apotex Inc 1-800-667-4708 or 416-401-7780 (follow prompts) Fax: 1-866-429-9133 or 416-401-3819 drug.safety@apotex.com www.apotex.com/ca/en/
Teva Teriflunomide Teva Canada Limited 1-800-268-4127 ext.3 Fax: 416-335-4472 Phv@tevacanada.com www.TevaCanada.com/Teriflunomide-Support		

We thank you for your collaboration in ensuring the highest level of patient safety.

Yours sincerely,

Mr. Bruce Valliant, Head of Pharmacovigilance and Medical Information, Pharmascience Inc.
Ms. Meera Kale, Sr. Manager, Quality and Pharmacovigilance, Natco Pharma (Canada) Inc.
Mr. Mauricio Ede-Filho, Chief Medical & Scientific Officer, Sandoz Canada Inc.
Mr. Suresh Arvapalli, Director, Technical, Marcan Pharmaceuticals Inc.
Dr. Rana Harb, Vice President, Technical Affairs (QA, RA & PV), Auro Pharma Inc.
Mr. Kiran Krishnan, PhD, Senior Vice President, Global Regulatory Affairs, Apotex Inc.
Mr. Dinakaran Munusamy, Associate Director, Pharmacovigilance (Local Safety Officer), Teva Canada